Union Health Ministry Study Finds Hexavalent Vaccine Could Boost UIP Efficiency and Cut Costs

Study Highlights Potential of Six‑in‑One Vaccine for India’s Immunisation Programme The Union Health Ministry, together with the George Institute for Global Health India, the Gates Foundation, Gavi , and John Snow India, released a study showing that introducing a hexavalent vaccine into the UIP could make childhood immunisation more efficient. Key Developments Study examined two scenarios: replacing the existing pentavalent vaccine and fractional IPV with the hexavalent vaccine in the primary schedule. Second scenario extended replacement to the DTP booster dose, using a hexavalent booster. Cost analysis covered government and household perspectives, including vaccine price, syringes, cold‑chain logistics , health‑worker time and caregiver time. Important Facts India vaccinates roughly 26 million infants each year under the UIP. The study found that the price of the hexavalent vaccine is the single biggest driver of total programme cost. A 50 % reduction in its price could make the operational savings—fewer injections, reduced cold‑chain burden, and less time for caregivers—greater than the higher purchase price. Benefits highlighted include: Fewer injections per visit, easing the burden on infants and caregivers. Reduced workload for frontline health workers , allowing them to focus on other health services. Lower cold‑chain requirements, freeing up logistics capacity. Time saved for caregivers, which can improve attendance at immunisation sessions. UPSC Relevance The findings intersect with several GS papers. Understanding the economics of vaccine procurement ties into GS3: Economy and health financing. The role of Gavi and public‑private collaborations illustrates policy‑making and implementation challenges covered in GS2: Polity . Moreover, the impact on frontline health workers and caregiver behaviour links to GS4: Ethics & Governance concerning equitable access and service delivery. Way Forward Policymakers should negotiate price reductions with manufacturers, leveraging bulk procurement and international partnerships. Parallelly, strengthening cold‑chain infrastructure and training health workers for combination‑vaccine administration will be essential. Continuous monitoring of caregiver preferences and cost‑effectiveness will guide scaling up the hexavalent vaccine across the UIP.